BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect ...

Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...

Cash generation is up 4% compared to September 2023, and net debt has fallen 89 million in the past year - Subscription models continue to drive growth and digital transformation: Santillana reports ...